Moreover, strategies to inhibit tumor necrosis factor-α (TNF-α) crucial target in IBD treatment - have been explored, including the use of nanobodies to neutralize TNF-α, with EcN’s type III secretion system enhancing nanobody delivery due to its gram-negative nature [20]. This evidence concerns the gene TNF and inflammatory bowel disease.